Danaher Strengthens Board of Directors with New Appointments of Daniel Comas and Robert Hershberg

Danaher Enhances Its Board of Directors

On October 9, 2026, Danaher Corporation announced the addition of two new members to its Board of Directors, Daniel L. Comas and Robert Hershberg, M.D., Ph.D. This strategic move expands Danaher's Board from 11 to 13 members and is part of the company's ongoing commitment to strengthen governance and leadership. The appointments reflect Danaher's dedication to fostering diverse perspectives that align with its business goals.

Overview of Appointees

Daniel L. Comas has an extensive history with Danaher, having joined the company in 1991. He served as Executive Vice President and held the role of Chief Financial Officer until December 2018. Over his career, Comas has been instrumental in leading various initiatives, including corporate development and risk management. Since his retirement in 2024, he has continued to provide valuable insight to Danaher as a consultant, ensuring a seamless transition and continuity of leadership.

Robert Hershberg brings significant expertise in the biopharmaceutical sector, having recently held leadership roles such as President and CEO of HilleVax, Inc. His prior experience at Celgene Corporation includes serving as Executive Vice President and Chief Scientific Officer. Hershberg's background in scientific innovation and clinical development enhances Danaher's capabilities in advancing healthcare solutions.

Strategic Implications

Steven M. Rales, Chairman of Danaher's Board, emphasized the importance of diverse experiences on the Board, stating that these appointments strengthen Danaher's strategic direction. With Comas's financial acumen and Hershberg's scientific expertise, Danaher is poised to enhance its innovation pipeline while driving value creation and long-term growth.

Rales also mentioned the acknowledgment of Alan G. Spoon, who will retire from the Board following the 2027 Annual Meeting. Spoon's contributions were vital to shaping Danaher's direction during his tenure, and the organization expresses gratitude for his leadership.

The selection of Comas and Hershberg aligns with Danaher's proactive approach to governance and board refreshment. The Nominating and Governance Committee is continuously assessing the Board's composition, ensuring it remains aligned with the company's evolving strategic goals.

Conclusion

Danaher Corporation's Board expansion signifies a pivotal moment in its commitment to innovation and operational excellence. By integrating diverse leadership with complementary skills, Danaher is reaffirming its mission to improve human health through advanced scientific solutions. The continued dedication to enhancing its Board structure reflects Danaher's strategy for sustained growth, benefiting both the company and its stakeholders.

For more information about Danaher's initiatives and corporate governance, visit Danaher's official website.